产品说明书

Zibotentan

Print
Chemical Structure| 186497-07-4 同义名 : ZD4054
CAS号 : 186497-07-4
货号 : A445755
分子式 : C19H16N6O4S
纯度 : 99%+
分子量 : 424.433
MDL号 : MFCD09955343
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 25 mg/mL(58.9 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • ET-A

    ET-A, IC50:21 nM
描述 Endothelin receptors are G protein-coupled receptors (GPCRs) of the β-group of rhodopsin receptors. It can bind to at least four endothelin ligands, ETA, ETB (ETB1, ETB2) and ETC [3]. Zibotentan (ZD4054) potently inhibited the binding of 125iodine-ET-1 to cloned human ETA expressed in mouse erythroleukaemic cells, with the pIC50 of 8.27 nM, but had no measurable affinity (pIC50>10 μM) for ETB [4]. Treatment with 1 μM Zibotentan for 24 hours inhibited proliferation of serum-starved HEY, OVCA 433, SKOV-3, and A-2780 cells. And Zibotentan at 1 μM decreased the endogenous ET-1-induced phosphorylation/activation of both kinases (AKT and p42/44MAPK) in HEY cells [5]. After oral administration of Zibotentan at a dose of ~3 mg/kg/d for 31days, MBP, SBP and DBP of the rats with hypertension decreased by 5.90 (4.75–7.05) mmHg, 5.91 (4.70–7.11) mmHg and 5.69 (4.26–7.12) mmHg, respectively, and the HR and RR rose by 9.23 (6.21–12.3) bpm and 4.62 (1.89–7.35) br/min, respectively [6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00055471 - Completed - -
NCT00055471 Prostatic Neoplasms ... 展开 >> Metastases, Neoplasm 收起 << Phase 2 Completed - United States, Ohio ... 展开 >> Research Site Cleveland, Ohio, United States, 44195 United States, Wisconsin Research Site Madison, Wisconsin, United States 收起 <<
NCT00929162 Patients With Advanced Ovarian... 展开 >> Cancer Sensitive to Platinum-based Chemotherapy 收起 << Phase 2 Terminated(Primary objective o... 展开 >>f the trial was not met and so there was no benefit in collecting further information) 收起 << - Germany ... 展开 >> Research Site Berlin, Germany Research Site Dresden, Germany Research Site Dusseldorf, Germany Research Site Essen, Germany Research Site Karlsruhe, Germany Research Site Kassel, Germany Research Site Kiel, Germany Research Site Lich, Germany Research Site Magdeburg, Germany Research Site Marburg, Germany Research Site Munchen, Germany Research Site Rostock, Germany Research Site Wiesbaden, Germany Italy Research Site Milano, MI, Italy Research Site Perugia, PG, Italy Research Site Aviano, PN, Italy Research Site Campobasso, Italy Research Site Modena, Italy Research Site Napoli, Italy Research Site Roma, Italy 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.56mL

4.71mL

2.36mL
参考文献

[1]Rosanò L, Di Castro V, et al. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood). 2006 Jun;231(6):1132-5.

[2]Morris CD, Rose A, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005 Jun 20;92(12):2148-52.

[3] Shepard DR, Dreicer R. Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin Investig Drugs. 2010 Jul;19(7):899-908

[4] Morris CD, Rose A, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005 Jun 20;92(12):2148-52

[5] Rosanò L, Di Castro V, et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther. 2007 Jul;6(7):2003-11

[6] Palmer JC, Tayler HM, et al. Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion. J Alzheimers Dis. 2020;73(3):1185-1199